We’re working to invent a world where cancer isn’t just treated, but cured.
Our focus on cancer research and treatments
We’re proud to deliver breakthrough innovations in oncology that are helping to extend the lives of patients with certain types of cancer.
We’re continuing to accelerate what we can achieve for the patients we serve, because everyone needs more ways to treat their cancer and, hopefully, more time.
Blood (hematologic) cancers start in the bone marrow where blood cells develop. The most common types of blood cancers are leukemia, lymphoma and myeloma. MSD is committed to advancing research in hematology and is studying new investigational candidates and new combinations that seek to improve care across these diverse diseases.
Breast cancer is the most common type of cancer worldwide. Treating this disease is challenging due to many subtypes responding differently to treatment. MSD aims to elevate breast cancer research through our broad clinical development program with the goal of improving care across certain early-stage and metastatic disease.
Gastrointestinal (GI) cancers
The most common GI cancers are esophageal, gastric (stomach), colorectal, pancreatic and liver. These cancers typically do not cause symptoms until they have reached an advanced stage, when treatments are usually less effective. MSD is advancing research through a broad clinical development program across GI cancers.
Head and neck cancer
Head and neck cancers refer to tumors that develop in or around the throat, larynx, nose, sinuses and mouth. MSD continues to innovate to advance treatment options for these patients.
Globally, lung cancer is the leading cause of cancer deaths, accounting for nearly 18% of all deaths from cancer. MSD has helped transform the way lung cancer is treated and is continuing to advance research, with the goal of improving outcomes for people affected by this disease.
Melanoma is a serious form of skin cancer, and rates of the disease have been continuing to rise over the last several decades. MSD has helped deliver meaningful advances for people with melanoma and is furthering research in skin cancers through our comprehensive clinical development program.
Globally, prostate cancer is the second most common cancer in people assigned male at birth. MSD is committed to advancing our clinical development program to find effective therapeutic approaches for this complex and difficult-to-treat disease.
Renal cell carcinoma
Renal cell carcinoma (RCC) is by far the most common type of kidney cancer; about 90% of kidney cancers cases are RCCs. MSD is dedicated to continuing efforts to discover effective treatments for this disease.
Supporting the cancer community
We work with the entire oncology community — advocacy partners, health care providers, governments and industry colleagues — to create programs that help patients and caregivers on their journeys, as well as provide grants to organizations that support patients with cancer.
Our commitment is unwavering
As long as there are still patients in hospitals, doctors desperate to add years to the lives of their patients, and a world where treatments aren’t accessible to all, we will be here: fighting with all we have to deliver more, sooner.